CorrectSequence CS-206 Sickle Cell Data

CorrectSequence Therapeutics, a clinical-stage biotechnology company, announced positive 15-month follow-up data for its high-precision base-editing therapy, CS-206, for Sickle cell disease. The first patient treated in China, a 21-year-old woman from Nigeria, has remained free of vaso-occlusive crises for over 15 months, achieving the primary efficacy endpoint. The therapy, which uses transformer Base Editing (tBE) technology, demonstrated favorable safety and efficacy, with no product-related adverse events. CS-206 works by precisely editing the HBG1/2 promoter region in autologous hematopoietic stem cells to reactivate gamma-globin expression and increase fetal hemoglobin levels, effectively suppressing red blood cell sickling. This approach avoids the DNA double-strand breaks associated with CRISPR-based therapies, offering a safer and more efficient treatment. CorrectSequence Therapeutics is also advancing CS-101 for Beta thalassemia, which has successfully cured over ten patients from China, Laos, Malaysia, and Pakistan, with all remaining transfusion-independent for over 15 months. The company is accelerating the global clinical development and commercialization of both therapies to provide more effective and affordable treatment options for hemoglobinopathy patients worldwide.